AI in Clinical Trials

Clinical trials are the most expensive, regulated, and human-dependent step in bringing a therapy to patients. A single Phase III trial can cost hundreds of millions of dollars, run across dozens of countries, and generate terabytes of data, while every day of delay means lost revenue and delayed patient access.

AI is not replacing the trial. It is compressing the parts that are pattern-heavy, repetitive, and data-intensive, so that human experts spend their time on judgment, relationship, and decision-making, not on reading thousands of pages of source documents or chasing missing queries.

This guide maps AI across the full trial lifecycle. Each stage links to a detailed field guide with implementation specifics, validation frameworks, and metrics that actually matter in production.

Roughly 80% of trials miss enrollment timelines, and about a third of Phase III sites never enroll a single patient. The bottleneck is matching complex eligibility criteria to messy, unstructured clinical records fast enough to compete with standard of care.

AI-driven recruitment uses NLP and LLMs to read EMR/EHR notes, pathology, and imaging summaries at population scale, surface candidates against protocol eligibility, and hand a ranked, pre-screened list to the study coordinator. Site selection uses predictive models over historical enrollment, therapeutic-area experience, and competing-trial density to rank sites before contracts are signed.

Clinical data management has moved from paper CRFs and SAS-centric workflows to cloud-native EDCs, real-time data streams, and agentic review systems. The goal is the same, clean, traceable, submission-ready data, but the speed and volume have changed by an order of magnitude.

AI in CDM means automated query generation, anomaly detection across patient profiles, and agentic systems that draft data-review summaries and route them to the medical monitor. Risk-Based Quality Management (RBQM) layers on top: AI keeps KRIs and QTLs computed in near real time, clusters sites by risk pattern, and flags anomalies classic thresholds miss.

Medical coding turns verbatim terms, adverse events, medical history, procedures, medications, into standardized dictionaries: MedDRA for safety, WHODrug for medications, ICD-10 for diagnoses, and CDISC controlled terminology for submission. It is precise, regulated, and historically slow.

AI coding systems map verbatim terms to dictionary terms with confidence scores, surface near-matches for the coder to validate, and learn from every override to improve the next batch. The human coder stays accountable for the final assignment; the AI collapses the time from receipt to lock.

Tables, Listings, and Figures (TLFs) are the backbone of the clinical study report and regulatory submission. Historically built by SAS programmers running macros against locked datasets, TLF generation is now being augmented by AI that drafts shell programs, suggests displays from protocol endpoints, and flags inconsistencies between output and statistical analysis plans.

Agentic reporting systems go further: they read the SAP, draft TLF shells, execute against the analysis dataset, highlight deviations from the planned displays, and route them to the statistical reviewer. The cycle time from database lock to first CSR draft collapses from weeks to days.

Pharmacovigilance is the discipline of collecting, assessing, and acting on adverse events across a product's lifecycle. The work is regulated end to end, EMA GVP, FDA 21 CFR 314.80/600.80, ICH E2B(R3), and the volume of cases is growing faster than safety teams can scale.

AI in PV automates ICSR intake from emails, portals, and literature; maps verbatim terms to MedDRA and WHODrug with confidence scores; drafts case narratives; and runs first-pass signal detection across safety databases. Agentic systems chain those steps into validated workflows where the safety physician reviews and signs off, and the audit trail satisfies any inspector.